News

Endurance tests that capture upper and lower body fatigue in spinal muscular atrophy patients — across ages, from children to adults, and degrees of disease severity — was proposed in a new study. These tests, combined, are intended to help researchers and clinicians better evaluate and treat fatigue, so as…

About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…

Treatment with Spinraza (nusinersen) benefits spinal muscular atrophy patients in terms of survival and quality of life of patients and caregivers, a study conducted in Sweden shows. However, Spinraza treatment was not considered cost-effective, as it exceed the willingness-to-pay threshold set by the Swedish…

The Revised Upper Limb Module (RULM) is better than the conventional Upper Limb Module (ULM) at assessing the arms’ function in a wider spectrum of patients with spinal muscular atrophy (SMA), a study found. The findings of the study, “Revised upper limb module for spinal muscular…

ArcherDX is expanding its product portfolio with newborn and screening tests to identify carriers of genetic variants linked to different disorders, including cystic fibrosis, spinal muscular atrophy, and fragile X syndrome. The company has acquired the genetics-based personalized medicine laboratory Baby Genes, which will operate under…

Scotland has joined the growing roster of countries making the spinal muscular atrophy (SMA) therapy Spinraza available to patients at low or no cost through that country’s public health system. Beginning in April, all SMA patients using NHS Scotland may start to receive Spinraza injections. Clearing the path for…

A new molecular compound, called LDN-2014, increases and stabilizes the levels of the survival motor neuron (SMN) protein, improving clinical outcomes in mouse models of mild and severe forms of spinal muscular atrophy (SMA), a study reports. The study, “Intraperitoneal delivery of a novel drug‐like compound improves disease severity in severe…

Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…

For people with spinal muscular atrophy (SMA), psychological well-being is not driven by socioeconomic factors or even illness characteristics. Instead, patients closely relate it to being content with their ability to participate in activities, and to their sense of autonomy, competence, and relatedness, researchers report. Their article, “…

Researchers have developed a platform called SMArtCARE that allows prospective monitoring of all spinal muscular atrophy patients regardless of their current treatment. The technology has the potential to shed new light on the disease’s natural history and medication’s influence. A description of the project was published in…